HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michihiro Yoshimura Selected Research

Spasm (Spasms)

1/2016Variant Aldehyde Dehydrogenase 2 (ALDH2*2) Is a Risk Factor for Coronary Spasm and ST-Segment Elevation Myocardial Infarction.
12/2014Pioglitazone, a peroxisome proliferator-activated receptor γ activator, suppresses coronary spasm.
1/2014Differences and interactions between risk factors for coronary spasm and atherosclerosis--smoking, aging, inflammation, and blood pressure.
5/2012High incidence of provoked coronary spasm in the presence of a stent after myocardial infarction: therapeutic and prognostic implications.
5/2010Nitrate tolerance as a possible cause of multidrug-resistant coronary artery spasm.
3/2009High incidence of repeat anginal attacks despite treatment with calcium-channel blockers in patients with coronary spastic angina.
5/2008Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers.
11/2007A novel genetic marker for coronary spasm in women from a genome-wide single nucleotide polymorphism analysis.
8/2007The endothelial nitric oxide synthase gene -786T/C polymorphism is a predictive factor for reattacks of coronary spasm.
7/2007Coronary spasm is associated with chronic low-grade inflammation.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michihiro Yoshimura Research Topics

Disease

37Heart Failure
03/2022 - 05/2002
29Atrial Fibrillation
01/2022 - 08/2008
24Myocardial Infarction
03/2019 - 06/2002
22Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 07/2002
18Spasm (Spasms)
01/2016 - 01/2002
14Coronary Artery Disease (Coronary Atherosclerosis)
01/2020 - 09/2003
14Hypertension (High Blood Pressure)
01/2015 - 05/2002
13Acute Coronary Syndrome
01/2020 - 09/2006
13Inflammation (Inflammations)
12/2018 - 01/2005
11Insulin Resistance
03/2022 - 12/2011
11Pathologic Constriction (Stenosis)
01/2022 - 02/2004
11Diabetes Mellitus
07/2018 - 05/2004
11Atherosclerosis
02/2015 - 01/2003
9Heart Diseases (Heart Disease)
01/2019 - 07/2009
8Tachycardia (Tachyarrhythmias)
01/2022 - 05/2009
8Left Ventricular Dysfunction
01/2021 - 05/2002
8Muscle Spasticity (Spastic)
01/2020 - 09/2003
8Thrombosis (Thrombus)
06/2018 - 03/2004
8Myocardial Ischemia (Ischemic Heart Diseases)
01/2017 - 04/2004
8Chest Pain (Chest Pains)
07/2007 - 09/2003
7Ischemia
03/2021 - 04/2012
7Fibrosis (Cirrhosis)
01/2020 - 02/2003
7Cardiomegaly (Heart Hypertrophy)
11/2016 - 02/2003
6Infarction (Infarctions)
01/2019 - 10/2003
6Type 2 Diabetes Mellitus (MODY)
01/2019 - 05/2005
6Coronary Stenosis (Coronary Artery Stenosis)
07/2018 - 11/2003
5Obesity
01/2022 - 10/2013
5Reperfusion Injury
01/2019 - 07/2002
5Essential Hypertension
11/2016 - 05/2002
5Hypertrophy
06/2014 - 03/2006
4Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2022 - 09/2006
4ST Elevation Myocardial Infarction
01/2016 - 01/2011
4Coronary Vasospasm (Coronary Artery Vasospasm)
05/2010 - 01/2002
3Fabry Disease (Fabry's Disease)
06/2022 - 01/2018
3Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
06/2022 - 05/2002
3Bradycardia
01/2022 - 05/2009
3Pulmonary Hypertension
07/2021 - 06/2018
3Arteriosclerosis
01/2021 - 10/2012
3Hypoxia (Hypoxemia)
01/2021 - 05/2005
3Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/2020 - 01/2010
3Hypercholesterolemia
01/2018 - 03/2009
3Flushing
12/2016 - 05/2015
3Glucose Intolerance
11/2007 - 01/2005
3Stable Angina
06/2004 - 07/2002

Drug/Important Bio-Agent (IBA)

24Brain Natriuretic Peptide (Natrecor)FDA Link
11/2021 - 05/2002
16AldosteroneIBA
01/2015 - 05/2002
12Glucose (Dextrose)FDA LinkGeneric
03/2022 - 11/2005
11Acetylcholine (Acetylcholine Chloride)FDA Link
01/2020 - 11/2003
9Uric Acid (Urate)IBA
01/2022 - 01/2010
8LipidsIBA
01/2022 - 01/2006
8Natriuretic PeptidesIBA
01/2021 - 05/2002
8C-Reactive ProteinIBA
12/2018 - 04/2004
7Biomarkers (Surrogate Marker)IBA
01/2021 - 07/2006
7Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2019 - 06/2004
7Angiotensin Receptor AntagonistsIBA
05/2013 - 09/2003
7AdiponectinIBA
05/2013 - 05/2004
7ThioredoxinsIBA
07/2007 - 09/2003
6NitratesIBA
03/2021 - 09/2003
6HDL CholesterolIBA
12/2016 - 05/2004
6Antihypertensive Agents (Antihypertensives)IBA
01/2016 - 01/2010
5oxidized low density lipoproteinIBA
01/2021 - 03/2009
5Adenosine Triphosphate (ATP)IBA
01/2021 - 10/2011
5Sirolimus (Rapamycin)FDA Link
07/2018 - 01/2011
5CreatinineIBA
03/2016 - 07/2002
5Calcium Channel Blockers (Blockers, Calcium Channel)IBA
10/2014 - 08/2007
4Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
01/2020 - 02/2014
4Aldehyde DehydrogenaseIBA
01/2020 - 05/2015
4Adenosine (Adenocard)FDA LinkGeneric
11/2016 - 08/2010
4SodiumIBA
06/2014 - 03/2006
4Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
11/2007 - 01/2003
4Plasminogen InactivatorsIBA
05/2004 - 01/2003
3Insulin (Novolin)FDA Link
01/2022 - 01/2017
3Malondialdehyde (Propanedial)IBA
01/2021 - 01/2015
3LDL Lipoproteins (beta Lipoproteins)IBA
01/2021 - 01/2015
3Oxygen (Dioxygen)IBA
01/2021 - 05/2013
3Atrial Natriuretic Factor (ANF)IBA
01/2021 - 07/2007
3GadoliniumIBA
12/2020 - 11/2011
3Eicosapentaenoic AcidIBA
01/2018 - 01/2016
3Arachidonic Acid (Vitamin F)IBA
01/2018 - 01/2016
3Indicators and Reagents (Reagents)IBA
01/2018 - 03/2006
3PotassiumIBA
01/2017 - 01/2010
3Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA
01/2015 - 03/2006
3Creatine Kinase (Creatine Phosphokinase)IBA
01/2015 - 01/2013
3Pioglitazone (Actos)FDA Link
12/2014 - 05/2013
3Hydrocortisone (Cortisol)FDA LinkGeneric
10/2014 - 02/2005
3Proteins (Proteins, Gene)FDA Link
06/2014 - 07/2009
3Oxidants (Oxidizing Agents)IBA
05/2013 - 02/2003
3omega-Chloroacetophenone (Mace)IBA
07/2011 - 09/2007
3Lipoproteins (Lipoprotein)IBA
03/2009 - 06/2004
3AntioxidantsIBA
07/2007 - 01/2004
3CholesterolIBA
04/2006 - 05/2004
3Cytochrome P-450 CYP11B2 (CYP11B2)IBA
01/2005 - 08/2002

Therapy/Procedure

28Therapeutics
06/2022 - 07/2002
24Catheter Ablation
01/2022 - 08/2008
10Stents
07/2018 - 07/2005
6Catheters
01/2022 - 05/2002
6Aftercare (After-Treatment)
11/2019 - 03/2005
5Radiofrequency Ablation
01/2022 - 11/2016
4Percutaneous Coronary Intervention
01/2021 - 06/2004
4Drug-Eluting Stents
07/2015 - 10/2009